https://www.selleckchem.com/products/inaxaplin.html Glu851Lys, as well as the genetic association of PPRCA to include HK1. While PPRCA has been previously reported to be associated with CRB1 gene, no previous relationship to the HK1 gene has been described. This case describes a pathogenic variant in HK1, a gene that has been associated with RP, but has not been previously reported in association with the PPRCA phenotype. This expands the phenotypes associated with HK1 pathogenic variant, p.Glu851Lys, as well as the genetic association of PPRCA to include HK1. While PPRCA has been previously reported to be associated with CRB1 gene, no previous relationship to the HK1 gene has been described. Melanoma-associated retinopathy (MAR) responds poorly to currently-available therapies, with continued chronic decline in visual function being the norm, despite treatment. The purpose of this report is to describe the excellent response of a patient with MAR to a triple therapy regimen of rituximab, intravenous immunoglobulin (IVIg), and intravitreal corticosteroids. Single interventional case report describing management of melanoma-associated retinopathy and the patient's response to this treatment. Retinal function was monitored by serial visual acuity, fundus exams, Goldmann visual fields, and electroretinography. A 65-year old man presented with new onset photopsia, decrease visual acuity and nyctalopia in both eyes in the setting of recently-diagnosed stage IIIB melanoma, initially treated with wide local excision and adjuvant interferon. He was diagnosed with melanoma-associated retinopathy that initially worsened during his course of interferon for treatment of the melanoma. We initiated triple therapy of rituximab, IVIg and intravitreal corticosteroids, and this resulted in full return of electroretinography function and resumption of 20/20 visual acuity OU. This is the first reported case of the utility of triple therapy with rituximab, IVIg, and intravitreal steroid